What's Happening?
Summit Therapeutics announced that data from its investigational bispecific antibody, ivonescimab, will be presented at the 2026 European Lung Cancer Congress. The data includes results from the HARMONi Phase III study, which evaluated ivonescimab combined
with chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC). The study showed improved intracranial progression-free survival in patients with brain metastases. Additional data on health-related quality of life and comparisons with other treatments will also be presented. Ivonescimab, developed by Akeso Inc., is designed to target PD-1 and VEGF, potentially offering a novel treatment approach for NSCLC.
Why It's Important?
The presentation of ivonescimab data at a major cancer congress underscores the potential impact of this investigational therapy on NSCLC treatment. By targeting both PD-1 and VEGF, ivonescimab may offer a new therapeutic option for patients with limited treatment choices. The positive results from the HARMONi study could influence clinical practice and encourage further research into bispecific antibodies. This development is significant for the oncology community, as it highlights ongoing advancements in cancer treatment and the potential for improved patient outcomes.
What's Next?
Following the presentation at ELCC 2026, Summit Therapeutics plans to continue its clinical development of ivonescimab, with ongoing Phase III trials and a pending Biologics License Application with the FDA. The company aims to expand its research into other cancer types and explore additional therapeutic combinations. The outcomes of these efforts could lead to regulatory approvals and broader clinical use of ivonescimab, potentially transforming the treatment landscape for NSCLC and other cancers.
